Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Revenue - Collaboration Agreement - Performance obligations (Details) - Astellas Collaboration Agreement $ in Millions		9 Months Ended
	Jan. 13, 2020 USD ($) item	Sep. 30, 2020 USD ($) item
Performance obligations
Number of co-development targets \| item	3
Number of independent targets \| item	2	2
Amount of transaction price of the agreement at inception	$ 50.0
Amount of transaction price allocated to performance obligation that has not been recognized as revenue		$ 62.9
Rights granted, first independent target
Performance obligations
Amount of transaction price allocated to performance obligation that has not been recognized as revenue		14.3
Rights granted, second independent target
Performance obligations
Amount of transaction price allocated to performance obligation that has not been recognized as revenue		14.3
Research services and rights granted under the co-exclusive license, first co-development target
Performance obligations
Amount of transaction price allocated to performance obligation that has not been recognized as revenue		20.5
Rresearch services and rights under the co-exclusive license, second co-development target
Performance obligations
Amount of transaction price allocated to performance obligation that has not been recognized as revenue		6.9
Rresearch services and rights under the co-exclusive license, third co-development target
Performance obligations
Amount of transaction price allocated to performance obligation that has not been recognized as revenue		$ 6.9